This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lundberg, P. Articles by Lerner, U. H. Search for Related Content PubMed PubMed Citation Articles by Lundberg, P. Articles by Lerner, U. H.

Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase-Activating Peptide Receptor Subtypes in Mouse Calvarial Osteoblasts: Presence of VIP-2 Receptors and Differentiation-Induced Expression of VIP-1 Receptors¹

Department of Odontology (P.L., I.L., H.M., U.H.L.), Oral Cell Biology, Umeå University, Umeå, Sweden; Department of Musculoskeletal Research (P.L., I.L., U.H.L.), National Institute for Working Life, Umeå, Sweden; and Bone and Mineral Centre (P.P.L., M.A.H.), Department of Medicine, The Rayne Institute, University College London, London WC1E 6JJ, United Kingdom

Address all correspondence and requests for reprints to: Pernilla Lund-berg, Department of Odontology, Oral Cell Biology, Umeå University, Umeå, SE-901 87, Sweden. E-mail: Pernilla Lundberg{at}odont.umu.se

Three distinct complementary DNAs for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been cloned and designated VIP-1 receptor (VIP-1R), VIP-2 receptor (VIP-2R), and PACAP receptor (PACAP-R). In the present study, we have characterized the binding sites on primary mouse calvarial osteoblasts for VIP and related peptides. By analyzing the cAMP response, the rank order of response observed was PACAP 38 > PACAP 27 > helodermin > VIP > helospectin > glucagon > PHI >>> secretin. The VIP-2R/PACAP-R antagonist, PACAP 6–38, inhibited both VIP- and PACAP-stimulated cAMP formation. Binding studies using an atomic force microscopy (AFM) technique showed high affinity binding for VIP and PACAP 38, but not for secretin. Radioligand binding studies using ¹²⁵I-VIP and ¹²⁵I-PACAP 38 demonstrated a more specific and higher affinity binding for PACAP 38 than for VIP. Secretin failed to inhibit both ¹²⁵I-VIP and ¹²⁵I-PACAP 38 binding. RT-PCR demonstrated that undifferentiated mouse calvarial osteoblasts express messenger RNA for VIP-2R, but not for VIP-1R or PACAP-R. When the osteoblasts were cultured for 20 days to induce bone noduli formation, VIP-1R, in addition to VIP-2R, were expressed when the nodules started to mineralize at 12 days. Taken together, these data demonstrate that mouse calvarial osteoblasts express functional VIP-2R with higher affinity binding for PACAP than for VIP and that the VIP-1R expression is induced during osteoblastic differentiation.

This article has been cited by other articles:

				C. Collet, C. Schiltz, V. Geoffroy, L. Maroteaux, J.-M. Launay, and M.-C. de Vernejoul The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation FASEB J, February 1, 2008; 22(2): 418 - 427. [Abstract] [Full Text] [PDF]

				P. Lundberg, S. J. Allison, N. J. Lee, P. A. Baldock, N. Brouard, S. Rost, R. F. Enriquez, A. Sainsbury, M. Lamghari, P. Simmons, et al. Greater Bone Formation of Y2 Knockout Mice Is Associated with Increased Osteoprogenitor Numbers and Altered Y1 Receptor Expression J. Biol. Chem., June 29, 2007; 282(26): 19082 - 19091. [Abstract] [Full Text] [PDF]

				M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]

				M. Sato, T. W. Gettys, and S. M. Lanier AGS3 and Signal Integration by G{alpha}s- and G{alpha}i-coupled Receptors: AGS3 BLOCKS THE SENSITIZATION OF ADENYLYL CYCLASE FOLLOWING PROLONGED STIMULATION OF A G{alpha}i-COUPLED RECEPTOR BY INFLUENCING PROCESSING OF G{alpha}i J. Biol. Chem., April 2, 2004; 279(14): 13375 - 13382. [Abstract] [Full Text] [PDF]

				S. Cecconi, G. Rossi, M. Barberi, L. Scaldaferri, and R. Canipari Effect of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Polypeptide on Mouse Preantral Follicle Development in Vitro Endocrinology, April 1, 2004; 145(4): 2071 - 2079. [Abstract] [Full Text] [PDF]

				R. V. Morris, C. B. Shoemaker, J. R. David, G. C. Lanzaro, and R. G. Titus Sandfly Maxadilan Exacerbates Infection with Leishmania major and Vaccinating Against It Protects Against L. major Infection J. Immunol., November 1, 2001; 167(9): 5226 - 5230. [Abstract] [Full Text] [PDF]